![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Vertex, Arbor Forge Potential $1.2 Billion Plus Deal for Gene-Editing Therapies
Vertex, Arbor Forge Potential $1.2 Billion Plus Deal for Gene-Editing Therapies
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
Vertex Pharmaceuticals has struck a deal with Arbor Biotechnologies to develop cell therapies using Arbor’s CRISPR gene-editing technology, building on a previous agreement in 2018.
Vertex plans to use Arbor’s technology to produce insulin-producing hypoimmune islet cells for type 1 diabetic medicines, next-generation sickle cell disease and beta thalassemia therapies and treatments for other diseases.
Vertex will pay an undisclosed upfront payment, with Arbor eligible to receive up to $1.2 billion in additional milestone-based payments.
Upcoming Events
-
21Oct